---
figid: PMC11922957__fphar-16-1531873-g005
figtitle: Mechanisms of the Draconis Resina on Cardiovascular Diseases
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11922957
filename: fphar-16-1531873-g005.jpg
figlink: /pmc/articles/PMC11922957/figure/F5/
number: F5
caption: 'Potential Mechanisms of the Draconis Resina on Cardiovascular Diseases.
  (A) Prevention of Thrombosis. Plasmin participates in the conversion of fibrinogen
  to fibrin degradation product. Normally, u-PA and t-PA could promote plasminogen
  conversion to plasmin. PAI-1 inhibits plasminogen conversion when combined with
  u-PA or t-PA (left). Loureirin B can reduce the binding of PAI-1 to u-PA or t-PA
  and promote Plasminogen conversion (right). (B) Inhibition of Inflammatory Responses.
  DR alleviates inflammation by regulating MAPKs, PPAR, NF-κB, JAK/STAT3, PI3K/AKT/mTOR
  signaling pathways. (C) Alleviating Oxidative Stress. DR improves oxidative stress
  by affecting MDA, SOD and LDH levels. (D) Improving Endothelial Function. LTC regulates
  the MAPK/IKK/IκB/NF-κB signaling pathway to improve endothelial function. (E) Anti-myocardial
  Fibrosis. DR regulates the TGF-β1/Smad signaling pathway affected by PIN1 and PAI-1
  against fibrosis. (AKT: Protein kinase B; DR: Draconis Resina; ICAM-1: Intercellular
  adhesion molecule - 1; IKK: IκB kinase; IL-1β: Interleukin - 1β; IL-6: Interleukin
  - 6; IL-8: Interleukin - 8; JAK: Janus kinase; LDH: Lactate dehydrogenase; LPS:
  Lipopolysaccharide; LTC: Longxue tongluo capsule; MAPK: Mitogen - activated protein
  kinase; MCP-1: Monocyte chemotactic protein - 1; MDA: Malondialdehyde; mTOR: Mammalian
  target of rapamycin; NF-κB: Nuclear factor - κB; ox-LDL: Oxidized low - density
  lipoprotein; PAI-1: Plasminogen activator inhibitor - 1; PI3K: Phosphoinositide
  3 - kinase; Pin1: Peptidyl - prolyl cis - trans isomerase NIMA - interacting protein
  1; PPAR: Peroxisome proliferator - activated receptor; PTGS: Prostaglandin - endoperoxide
  synthase; ROS: Reactive oxygen species; SATAT: Signal transducer and activator of
  transcription; SOD: Superoxide dismutase; TGF-β1: Transforming growth factor - β1;
  TNFα: Tumor necrosis factor - α; t-PA: Tissue - type plasminogen activator; TβR:
  Transforming growth factor - β receptor; u-PA: Urokinase - type plasminogen activator;
  VCAM-1: Vascular cell adhesion molecule - 1)'
papertitle: Potential therapeutic mechanisms of Draconis Resina in cardiovascular
  diseases-a narrative review
reftext: Jing Wang, et al. Front Pharmacol. 2025;16(NA).
year: '2025'
doi: 10.3389/fphar.2025.1531873
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media SA
keywords: draconis resina | loureirin | cardiovascular diseases | pharmacology | cardioprotective
  effect
automl_pathway: 0.8945177
figid_alias: PMC11922957__F5
figtype: Figure
redirect_from: /figures/PMC11922957__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11922957__fphar-16-1531873-g005.html
  '@type': Dataset
  description: 'Potential Mechanisms of the Draconis Resina on Cardiovascular Diseases.
    (A) Prevention of Thrombosis. Plasmin participates in the conversion of fibrinogen
    to fibrin degradation product. Normally, u-PA and t-PA could promote plasminogen
    conversion to plasmin. PAI-1 inhibits plasminogen conversion when combined with
    u-PA or t-PA (left). Loureirin B can reduce the binding of PAI-1 to u-PA or t-PA
    and promote Plasminogen conversion (right). (B) Inhibition of Inflammatory Responses.
    DR alleviates inflammation by regulating MAPKs, PPAR, NF-κB, JAK/STAT3, PI3K/AKT/mTOR
    signaling pathways. (C) Alleviating Oxidative Stress. DR improves oxidative stress
    by affecting MDA, SOD and LDH levels. (D) Improving Endothelial Function. LTC
    regulates the MAPK/IKK/IκB/NF-κB signaling pathway to improve endothelial function.
    (E) Anti-myocardial Fibrosis. DR regulates the TGF-β1/Smad signaling pathway affected
    by PIN1 and PAI-1 against fibrosis. (AKT: Protein kinase B; DR: Draconis Resina;
    ICAM-1: Intercellular adhesion molecule - 1; IKK: IκB kinase; IL-1β: Interleukin
    - 1β; IL-6: Interleukin - 6; IL-8: Interleukin - 8; JAK: Janus kinase; LDH: Lactate
    dehydrogenase; LPS: Lipopolysaccharide; LTC: Longxue tongluo capsule; MAPK: Mitogen
    - activated protein kinase; MCP-1: Monocyte chemotactic protein - 1; MDA: Malondialdehyde;
    mTOR: Mammalian target of rapamycin; NF-κB: Nuclear factor - κB; ox-LDL: Oxidized
    low - density lipoprotein; PAI-1: Plasminogen activator inhibitor - 1; PI3K: Phosphoinositide
    3 - kinase; Pin1: Peptidyl - prolyl cis - trans isomerase NIMA - interacting protein
    1; PPAR: Peroxisome proliferator - activated receptor; PTGS: Prostaglandin - endoperoxide
    synthase; ROS: Reactive oxygen species; SATAT: Signal transducer and activator
    of transcription; SOD: Superoxide dismutase; TGF-β1: Transforming growth factor
    - β1; TNFα: Tumor necrosis factor - α; t-PA: Tissue - type plasminogen activator;
    TβR: Transforming growth factor - β receptor; u-PA: Urokinase - type plasminogen
    activator; VCAM-1: Vascular cell adhesion molecule - 1)'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PLAU
  - SERPINE1
  - PLG
  - PLAT
  - FGA
  - FGB
  - FGG
  - TNF
  - IL6
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT3
  - IRF6
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CXCL8
  - IL1A
  - IL1B
  - PTGS2
  - NFKB1
  - SOD1
  - SOD2
  - SOD3
  - LDHA
  - LDHB
  - LDHC
  - ICAM1
  - VCAM1
  - CCL2
  - PIN1
  - PDZD2
  - TGFB1
  - SMAD2
  - SMAD3
  - SMAD4
  - Fibrin
  - TNF-a
  - LPS
  - ROS
  - MDA
  - Atherosclerosis
---
